Epicutaneous Allergen Patch for Pediatric Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergy prevention methods, such as subcutaneous and sublingual immunotherapy, are either risky, costly, or less effective in preventing the development of allergies in children, particularly for food and respiratory allergens, and lack a prophylactic approach to prevent the onset of multiple allergies.
Innovation Solution
Epicutaneous administration of allergens to children, particularly those under 6 years old, to induce a non-allergen-specific immune response and stimulate the production of regulatory T cells, thereby preventing the development of further allergies by desensitizing them to initial allergens and protecting against other allergens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subcutaneous immunotherapy is used, then desensitization effectiveness is improved, but safety deteriorates due to risk of anaphylactic reactions and deaths
Solution Approach 1:
The patent introduces the skin as an intermediary route for allergen delivery, using epicutaneous application as a mediator between the allergen and the immune system. This intermediate approach avoids the direct bloodstream exposure caused by subcutaneous injection, thereby reducing anaphylactic risk while maintaining desensitization effectiveness through gradual immune system exposure.
Solution Approach 2:
The patent employs disposable adhesive patches for epicutaneous application, which are single-use, easy to apply, and eliminate the need for repeated physician interventions. This disposable approach improves safety by ensuring consistent dosing without contamination risk and reduces the harmful effects associated with repeated needle injections.
2Reliability
If subcutaneous immunotherapy is used, then desensitization effectiveness is improved, but device complexity and cost increase due to physician intervention requirements
Solution Approach 1:
The patent enables self-administration of immunotherapy through epicutaneous patches that patients can apply themselves at home. This self-service approach eliminates the need for physician interventions at each injection, reducing device complexity and operational cost while maintaining treatment effectiveness through consistent, patient-controlled allergen delivery.
Solution Approach 2:
The patent extracts the physician intervention step from the immunotherapy process by using a self-applied epicutaneous patch system. This extraction removes the complexity of medical procedures, allowing patients to independently manage their desensitization treatment while maintaining clinical effectiveness.
3Object-affected harmful factors
If sublingual immunotherapy is used, then safety is improved with fewer adverse reactions, but effectiveness deteriorates requiring larger allergen amounts
Solution Approach 1:
The patent applies local quality by targeting specific skin areas for epicutaneous allergen delivery, creating localized immune responses that are both safe and effective. This localized approach improves upon sublingual therapy by concentrating the allergen delivery to specific epidermal regions, achieving effective desensitization with smaller allergen amounts while maintaining low adverse reaction rates.
4Reliability
If conventional immunotherapy routes are used, then treatment of existing allergies is effective, but prophylactic prevention of multiple allergies is not achieved
Solution Approach 1:
The patent achieves universality by demonstrating that epicutaneous immunotherapy can simultaneously treat existing allergies and prevent multiple future allergies. This multi-functional approach allows a single treatment route to serve both therapeutic and prophylactic purposes, improving adaptability compared to conventional routes that are limited to treating specific existing allergies.
Data Source
Figure 1
Figure 2-a~2-b
Figure 3-a~3-b
AI summary
The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.